Breaking News Instant updates and real-time market news.

ALPN

Alpine Immune Sciences

$6.95

0.13 (1.91%)

16:21
08/09/18
08/09
16:21
08/09/18
16:21

Alpine Immune reports Q2 EPS (57c), consensus (43c)

Reports Q2 revenue $390,000, consensus $210,000. "During the first six months of this year, we continued to execute with important advancements that support taking our programs into clinical trials," said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. "Our lead program ALPN-101, a dual ICOS/CD28 antagonist for the treatment of autoimmune/inflammatory disease, is rapidly advancing toward our company's first human clinical trials. Our lead oncology program, ALPN-202, is a novel molecule designed to block the inhibitory immune checkpoints PD-L1 and CTLA-4, and to provide PD-L1-dependent T cell activation via the CD28 costimulatory receptor. Together, we believe these two molecules place Alpine on the cusp of the next generation of immunotherapy. I'm also excited about the addition of Mark Litton as President and Chief Operating Officer, which comes at an important time for Alpine. I am confident we have the right people and strategy in place as we work to deliver meaningful value to our investors over the long term."

  • 14

    Aug

ALPN Alpine Immune Sciences
$6.95

0.13 (1.91%)

09/22/17
STFL
09/22/17
UPGRADE
STFL
Buy
Alpine Immune Sciences upgraded to Buy at Stifel
As previously reported, Stifel analyst Thomas Shrader set a Buy rating and $16 price target on Alpine Immune Sciences (ALPN), the "financial continuation" of Nivalis. That is up from the prior rating of Hold and $3.25 on its predecessor. He sees the company's focus on immune system modulation as a "timely and a powerful approach" to build additional specificity into current immunomodulatory drugs. Shrader adds that the company's collaboration with Kite Pharma (KITE) seems "more important than ever" after Gilead (GILD) comments that they plan to use excess R&D capacity to "keep up" in the evolving CAR-T/TCR space.
05/17/18
WEDB
05/17/18
INITIATION
WEDB
Outperform
Alpine Immune Sciences initiated with an Outperform at Wedbush
05/18/18
WEDB
05/18/18
INITIATION
Target $13
WEDB
Outperform
Wedbush starts Alpine Immune Sciences with Outperform, $13 target
Wedbush analyst Robert Driscoll last night initiated Alpine Immune Sciences with an Outperform rating and $13 price target. The analyst views current share levels as attractive with the company's initial candidates entering the clinic in the next 12 months. He expects Alpine's "versatile platform to create a range of additional candidates to drive significant value going forward." The company's protein-based therapeutics could potentially modulate the immune synapse more effectively than conventional immunotherapeutics for the treatment of cancer and autoimmune/inflammatory diseases, Driscoll told investors in a research note.
06/28/18
OPCO
06/28/18
INITIATION
Target $13
OPCO
Outperform
Alpine Immune Sciences initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Alpine Immune Sciences with an Outperform rating and $13 price target, citing his belief that the company's differentiated platform technology could significantly improve the performance of checkpoint modulators, which have revolutionized the treatment of certain cancers and autoimmune disorders.

TODAY'S FREE FLY STORIES

CIEN

Ciena

$34.90

2.765 (8.60%)

17:20
12/13/18
12/13
17:20
12/13/18
17:20
Recommendations
Ciena analyst commentary  »

Piper boosts Ciena target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TROX

Tronox

$7.77

0.05 (0.65%)

17:14
12/13/18
12/13
17:14
12/13/18
17:14
Hot Stocks
Tronox CFO Timothy Carlson buys 21,000 shares of company stock »

Tronox CFO Timothy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$39.39

-0.61 (-1.53%)

, WDC

Western Digital

$39.95

-1.01 (-2.47%)

17:13
12/13/18
12/13
17:13
12/13/18
17:13
Initiation
Seagate, Western Digital initiated  »

Seagate, Western Digital…

STX

Seagate

$39.39

-0.61 (-1.53%)

WDC

Western Digital

$39.95

-1.01 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

UHS

Universal Health

$132.00

0.765 (0.58%)

17:12
12/13/18
12/13
17:12
12/13/18
17:12
Downgrade
Universal Health rating change  »

Goldman downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCG

WellCare

$244.34

-0.42 (-0.17%)

17:09
12/13/18
12/13
17:09
12/13/18
17:09
Upgrade
WellCare rating change  »

Goldman upgrades WellCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$42.25

-0.62 (-1.45%)

17:08
12/13/18
12/13
17:08
12/13/18
17:08
Hot Stocks
Acacia reports 400G single carrier DWDM transmission on Marea cable »

Acacia announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMAX

Imax

$19.35

-0.2 (-1.02%)

17:07
12/13/18
12/13
17:07
12/13/18
17:07
Hot Stocks
Imax to close remaining VR locations, sees one-time charges of $6.9M in Q4 »

In connection with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIK

Tel-Instrument

$3.05

(0.00%)

17:06
12/13/18
12/13
17:06
12/13/18
17:06
Hot Stocks
Tel-Instrument receives $615K test set order »

Tel-Instrument has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$14.87

-0.13 (-0.87%)

17:04
12/13/18
12/13
17:04
12/13/18
17:04
Upgrade
CytomX Therapeutics rating change  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$50.74

-0.67 (-1.30%)

17:03
12/13/18
12/13
17:03
12/13/18
17:03
Hot Stocks
Quidel announces availability of Triage PLGF assay »

Quidel announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBHT

J.B. Hunt

$95.89

-2.36 (-2.40%)

17:02
12/13/18
12/13
17:02
12/13/18
17:02
Hot Stocks
J.B. Hunt announces arbitration update with BNSF Railway Company »

J.B. Hunt Transport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CWT

California Water Service

$48.57

0.77 (1.61%)

17:02
12/13/18
12/13
17:02
12/13/18
17:02
Hot Stocks
CPUC approves Cal Water provision of water service to Travis Air Force Base »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEU

NewMarket

$393.05

-6.78 (-1.70%)

17:02
12/13/18
12/13
17:02
12/13/18
17:02
Hot Stocks
NewMarket approves new $500M stock repurchase program »

NewMarket approved a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMT

Core Molding

$7.90

-0.4 (-4.82%)

17:01
12/13/18
12/13
17:01
12/13/18
17:01
Hot Stocks
Core Molding names Tom Cellitti vice chairman »

Core Molding Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADXS

Advaxis

$0.36

-0.0071 (-1.93%)

, AMGN

Amgen

$197.47

1.06 (0.54%)

17:00
12/13/18
12/13
17:00
12/13/18
17:00
Hot Stocks
Advaxis receives notice of termination from Amgen relating to ADXS-NEO program »

On December 10, Advaxis…

ADXS

Advaxis

$0.36

-0.0071 (-1.93%)

AMGN

Amgen

$197.47

1.06 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GLNCY

Glencore

$0.00

(0.00%)

16:58
12/13/18
12/13
16:58
12/13/18
16:58
Periodicals
China's GEM halts buying cobalt from Glencore, Reuters reports »

Chinese battery firm GEM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$130.06

-6.15 (-4.52%)

16:58
12/13/18
12/13
16:58
12/13/18
16:58
Syndicate
RH says no longer exploring $300M convertible notes offering »

RH announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXON

Axovant Sciences

$1.13

-0.07 (-5.83%)

16:57
12/13/18
12/13
16:57
12/13/18
16:57
Syndicate
Axovant Sciences files to sell common stock, no amount given »

Jefferies and Guggenheim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$96.50

2.47 (2.63%)

16:56
12/13/18
12/13
16:56
12/13/18
16:56
Upgrade
Procter & Gamble rating change  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

JBHT

J.B. Hunt

$95.89

-2.36 (-2.40%)

16:55
12/13/18
12/13
16:55
12/13/18
16:55
Hot Stocks
Breaking Hot Stocks news story on J.B. Hunt »

J B Hunt Transport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$37.94

0.26 (0.69%)

16:53
12/13/18
12/13
16:53
12/13/18
16:53
Initiation
GlaxoSmithKline initiated  »

GlaxoSmithKline initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$265.41

-0.12 (-0.05%)

16:53
12/13/18
12/13
16:53
12/13/18
16:53
Periodicals
Federal prosecutors investigating Trump inauguration spending, WSJ reports »

Federal prosecutors in…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$265.41

-0.12 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MG

Mistras

$14.94

-0.79 (-5.02%)

16:52
12/13/18
12/13
16:52
12/13/18
16:52
Conference/Events
Mistras to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRX

Agile Therapeutics

$0.83

-0.0037 (-0.45%)

16:51
12/13/18
12/13
16:51
12/13/18
16:51
Hot Stocks
Agile Therapeutics to resubmit the Twirla NDA in 1H19 »

On December 13, Agile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,660.00

-3.4 (-0.20%)

16:49
12/13/18
12/13
16:49
12/13/18
16:49
Periodicals
Amazon ran sting to identify counterfeit textbooks, CNBC says »

Amazon conducted a sting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.